<DOC>
	<DOC>NCT01370902</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this dose-escalating trial is to assess the safety, tolerability, pharmacokinetics (the rate at which the body eliminates the trial drug) and pharmacodynamics (the effect of the investigated drug on the body) of single and repeated doses of NNC141-0100 in subjects with Rheumatoid Arthritis.</brief_summary>
	<brief_title>Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<criteria>A diagnosis of rheumatoid arthritis (RA) according to the American College of Rheumatology (ACR1987 classification) of at least 3 months duration prior to randomisation Active Rheumatoid Arthritis (RA) characterised by a DAS28CRP (Disease Activity Score of 28 joints, calculated with CRP (Creactive protein) value) greater than or equal to 3.2 Females must be postmenopausal or surgically sterile (postmenopausal for at least 1 year) or be willing to use highly effective method of birth control Males must be willing to use highly effective contraception Subjects on stable doses of methotrexate (7.5 to 25 mg/week, both inclusive) for at least 4 weeks prior to randomisation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>